Google DeepMind 发布 AlphaGenome 2 DNA 序列模型

DeepMind 的 AlphaGenome 2 升级了基因组突变预测：能 zoom 到单一细胞类型，而不是像初代那样混合整块组织，捕捉调控突变的量差不多翻倍，还能靠少量样本泛化到没见过的细胞。做遗传研究、精准医疗的人可以关注，这是 AlphaFold 路线在基因组学上的延续。

The Rundown AI@therundownaiSource

API-only access means labs can integrate regulatory predictions into pipelines without GPU infrastructure or model hosting, which shifts the cost of entry from engineering to analysis. Computational biologists, university groups, and biotech research teams working on gene regulation can start experimenting immediately under non-commercial terms. Anyone planning applied or commercial genomics work should check DeepMind's licensing terms first, as the restriction currently blocks revenue-generating use.

Sundar Pichai@sundarpichaiSource

Cell-specific variant interpretation is a bottleneck in translating genome sequencing into clinical insight, and AlphaGenome 2 targets exactly that gap. Genomics labs, computational biologists, and biotech teams evaluating disease-causing mutations can use it to prioritise variants by affected tissue. Compared with AlphaFold, which resolved protein structure, this model moves DeepMind's tooling upstream into gene regulation, a space where competitors like Enformer and Evotec partnerships have been active.

Official accountGoogle DeepMind@GoogleDeepMindSource

The interesting shift is that the model's value comes from context — the same variant can be scored across many cell types, enabling tissue-aware interpretation of disease-linked variants that single-context tools miss. Computational biologists, genetics labs and variant-interpretation teams can start experimenting immediately through the free Colab tutorials without infrastructure setup. Commercial users are excluded from the current licence, so biotech teams should treat it as a research preview and watch how DeepMind prices commercial access later.

Official accountGoogle DeepMind@GoogleDeepMindSource